Phase 3 N=60 Interleukin-1 Blockade in Recently Decompensated Heart Failure
Heart Failure
Primary: Interval Changes in Peak Oxygen Consumption (VO2) — 14.05; 14.45; 13.3; 14.85 mL/kg/min — p=>0.20
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=31 Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Phase 2 N=75 Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea
Sleep Apnea, Obstructive
Primary: Change in Apnea/Hypopnea Index (AHI) — 7.99; -1.71; -5.21 events/hour
Phase 4 N=25 OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
Diabetes Mellitus, Type 2
Primary: Geometric Means of Area Under Plasma Concentration Time Curve of the Test Drug (Oxemet) to the Reference Drug (Glafornail) From Time Zero to the Time of Last…
Phase 2 N=78 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
N/A N=120 To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score After 10 Minutes — -0.46; -0.02 score on a scale — p=<.0001
Phase 2 N=21 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants
Phase 2 N=50 Amitriptyline to Prevent Headache After Traumatic Brain Injury
Brain Injuries · Post-Traumatic Headache
Primary: Frequency of Headaches — 10 Participants — p=.101
N/A N=27 Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Dry Eye Syndrome
Primary: Change From Baseline of the Ocular Surface Disease Index Score at Day 45 — -28.4; -5.8 units on a scale — p=0.61
Phase 3 N=759 Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Prevention of : Herpes-Zoster
Primary: Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3 — 498.8; 523.3; 555.3; 410.5 gpELISA units/mL…
N/A N=15 Metformin for Rising PSA Remote Trial
Prostate Cancer
Primary: Number of Participants That Completed All Telemedicine Visits — 12 Participants
N/A N=22 Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Binge Eating Disorder
Primary: Binge Eating Frequency (Continuous) — 4.4; 3.0 binge eating days (out of 28)
Phase 3 N=302 Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
Phase 2 N=442 Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12) — 100.0; 100.0; 68.8; 71.4 Percentage of Participants
N/A N=366 Incubator Weaning of Moderately Preterm Infants
Infant, Newborn · Infant, Moderate Preterm
Primary: Length of Hospital Stay (LOS) From Birth to Discharge (up to 120 Days) — 43; 41 days